MARK BYRON JENNINGS MD NPI 1336379783

NPI Details

Mark Byron Jennings, MD is an internal medicine in Allen, TX with 16 years of experience. The provider is a physician who provides long-term, comprehensive care in the office and the hospital, managing both common and complex illness of adolescents, adults and the elderly. Internists are trained in the diagnosis and treatment of cancer, infections and diseases affecting the heart, blood, kidneys, joints and digestive, respiratory and vascular systems. They are also trained in the essentials of primary care internal medicine, which incorporates an understanding of disease prevention, wellness, substance abuse, mental health and effective treatment of common problems of the eyes, ears, skin, nervous system and reproductive organs. Mark Byron Jennings, MD NPI is 1336379783. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE
Graduation Year:2009

The provider's business location address is:

1105 CENTRAL EXPY N STE 235
ALLEN, TX
ZIP 75013-135
Phone: (972) 747-6042
Fax: (972) 747-6043

The NPI 1336379783 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, granisetron, extended-release, 0.1 mg (HCPCS:J1627)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg (HCPCS:Q5116)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml (HCPCS:A9579)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Magnesium level (HCPCS:83735)
• Phosphate level (HCPCS:84100)
• Uric acid level, blood (HCPCS:84550)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Ct scan of chest with contrast (HCPCS:71260)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Unclassified drugs (HCPCS:J3490)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Blood creatinine level (HCPCS:82565)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month (HCPCS:99426)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Ct scan of chest without contrast (HCPCS:71250)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Mri scan of brain before and after contrast (HCPCS:70553)
• Urine microalbumin (protein) analysis (HCPCS:82044)
• Red blood count, automated test (HCPCS:85045)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Mri scan of abdomen before and after contrast (HCPCS:74183)

The enumeration date for this NPI number is 7/20/2009 and was last updated on 9/12/2012.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.